Full Prescribing Info
Dosage/Direction for Use

Giardiasis, Cryptosporidiosis
Adult: 500 mg every 12 hr for 3 days.
Child: 1-3 yr: 100 mg every 12 hr; 4-11 yr: 200 mg every 12 hr; ≥12 yr: 500 mg every 12 hr. All doses to be taken for 3 days.
Should be taken with food.
Special Precautions
Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.
Adverse Reactions
Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.
Drug Interactions
May possibly interact with highly protein-bound drugs e.g. warfarin.
Food Interaction
Increased AUC with food.
Nitazoxanide is an antiprotozoal agent. Both nitazoxanide and its active metabolite (tizoxanide) interfere with the pyruvate:ferredoxin 2-oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic metabolism in susceptible organisms.
Absorption: Absorbed from the GI tract (oral). Extent of absorption enhanced with food; peak plasma concentrations of tizoxanide and glucuronide metabolite after 1-4 hr.
Distribution: Protein-binding: >99%.
Metabolism: Rapidly hydrolysed to tizoxanide (active desacetyl metabolite) which partially undergoes conjugation, primarily by glucuronidation.
Excretion: Via faeces (2/3 of an oral dose); via urine (remaining dose).
Oral: Suspension: Store at 15-30°C (59-86°F). Tablet: Store at room temperature.
CIMS Class
ATC Classification
P01AX11 - nitazoxanide ; Belongs to the class of other agents used in the treatment amoebiasis and other protozoal diseases.
Disclaimer: This information is independently developed by CIMS based on nitazoxanide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in